Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,032.00
Bid: 12,032.00
Ask: 12,034.00
Change: -124.00 (-1.02%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Vaccine developments keep dollar down; Kiwi hits 2-year high

Mon, 23rd Nov 2020 12:05

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E
(Updates prices, adds comment and chart)

By Elizabeth Howcroft

LONDON, Nov 23 (Reuters) - Risk appetite in currency markets
was boosted by progress towards a COVID-19 vaccine rollout even
as PMI data showed a sharp contraction in euro zone business
activity as a result of lockdown restrictions.

AstraZeneca on Monday said that its vaccine could be
about 90% effective and it will prepare to submit data to
authorities around the world that have a framework for
conditional or early approval.

This was the latest in a string of positive vaccine
developments after Moderna Inc said on Nov. 16 that its
experimental vaccine was 94.5% effective, a week after Pfizer
Inc and BioNTech SE said their candidate had
demonstrated greater than 90% efficacy, rising to 95% with
analysis of full trial data.

Sentiment had been strong overnight after a top U.S. health
official said that vaccinations could begin by mid-December.

"From a market perspective, the vaccine news cements our
bullish view on most pro-cyclical currencies against the dollar
through the turn of the year," Deutsche Bank FX strategists
Robin Winkler and George Saravelos said in a note to clients.

The dollar, which fell 0.4% against a basket of currencies
last week, continued its downward trend as traders' risk
appetite grew and was down 0.3% at 92.086 by 1132 GMT.

The dollar also lost out to the yen, with the pair changing
hands at 103.725.

The New Zealand dollar surged to a two-year high after
strong retail sales data, reducing the risk of further policy
easing. It continued to strengthen in the European session,
hitting a fresh two-year high of 0.6966 per dollar.

The Australian dollar - a liquid proxy for risk - was up
0.3% at 0.73255.

The Euro-dollar rate crossed $1.19 for the first time in two
weeks and was up 0.4% at $1.19005 by 1134 GMT.

"We won’t really unlock euro-dollar much higher unless we
can solve the EU-UK trade deal, and the EU budget and recovery
fund – those are probably the two things that’ll really get it
moving," said Kit Juckes, head of FX strategy at Societe
Generale.

European Union leaders will continue to discuss the bloc's
1.8 trillion euro ($2.14 trillion) COVID-19 recovery plan, which
has been vetoed by Poland and Hungary, German Chancellor Angela
Merkel said last week.

The pound was boosted by hopes for a Brexit deal
. The EU's chief Brexit negotiator said that
fundamental divergences remain but both sides were pushing hard
for a deal.

Euro zone PMI data showed that the bloc's business activity
contracted sharply in November - even more than expected - as
lockdown measures to control the spread of COVID-19 forced many
businesses in the service industry to close.

The bloc's economy is on track for its first double-dip
recession in nearly a decade as the coronavirus second wave
sweeps across Europe, a Reuters poll suggested last week.

The yuan, meanwhile, was dented by fresh U.S.-China
tensions.

The Trump administration is close to declaring that 89
Chinese aerospace and other companies have military ties,
restricting them from buying a range of U.S. goods and
technology, according to a draft copy of the list seen by
Reuters.

The dollar was up about 0.1% against the offshore yuan at at
6.5597 by 1140 GMT.
($1 = 0.8405 euros)

(Reporting by Elizabeth Howcroft
Editing by William Maclean and David Goodman)

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.